Registered Zambia · ZAMRA

Vectormune FP-MG + AE Vaccine

Mycoplasma gallisepticum virus 102.7 TCID50, Avian encephalomyelitis virus 102.7 TCID50

What it does

Avian is a medication used to treat various health conditions related to the avian species.

Commonly used for: treats diseases in birds, supports avian health

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
346/732V
Registration date
2026-10-02
Expiry date
2031-10-01
Status
Registered/Compliant
Active ingredient
Mycoplasma gallisepticum virus 102.7 TCID50, Avian encephalomyelitis virus 102.7 TCID50
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Ceva Animal Health
Country of origin
South Africa

Source: Zambia Medicines Regulatory Authority · fetched 2026-10-05 03:40:39 · updated 2026-10-19 03:40:41

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About avian

Avian is a medication used to treat various health conditions related to the avian species.

What it treats

  • treats diseases in birds
  • supports avian health

How it works

Avian works by addressing specific health issues in birds, promoting recovery and well-being.

Who it's for

This medication is for veterinarians and pet owners caring for birds.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About encephalomyelitis

Encephalomyelitis is an inflammatory condition affecting the brain and spinal cord.

What it treats

  • inflammation of the brain and spinal cord (encephalomyelitis)

How it works

The exact mechanism is not fully understood, but it involves the immune system attacking the central nervous system.

Who it's for

This condition can affect anyone, but certain viral infections can increase the risk.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About gallisepticum

Gallisepticum is a medication often used as an antiseptic.

What it treats

  • infections
  • sepsis
  • bacterial infections

How it works

It helps to kill or prevent the growth of bacteria, reducing infections in the body.

Who it's for

This medication is typically used for individuals with bacterial infections or those at risk of sepsis.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About mycoplasma

Mycoplasma is a type of bacteria that can cause various infections, particularly in the respiratory system.

What it treats

  • respiratory infections
  • urethritis (inflammation of the urethra)
  • pneumonia

How it works

Mycoplasma bacteria can disrupt normal cell function and lead to illness.

Who it's for

This condition can affect anyone, but it is more common in young adults and those with weakened immune systems.

Cautions

  • • May require specific tests for accurate diagnosis.
  • • Treatment may vary based on the type of infection.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About virus

Viruses are microscopic organisms that can cause infections in humans, animals, and plants.

What it treats

  • viral infections
  • common cold
  • influenza (flu)
  • HIV/AIDS
  • hepatitis

How it works

Viruses invade living cells and use them to reproduce, which can lead to illness.

Who it's for

Viruses can affect anyone, but some groups, like those with weakened immune systems, are more at risk.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: avian

Avian is a term that generally refers to substances derived from birds or targeting avian species. In a pharmacological context, it may relate to medications or treatments aimed at avian diseases or conditions in veterinary medicine. However, no specific drug named 'avian' is recognized in human medicine or standard pharmacological references.

Dosage

Children: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Adults: Refer to specific veterinary guidelines or pharmacological references for dosing information, as it varies widely based on the specific drug and condition being treated.

Mechanism of action

The mechanism of action for avian-related treatments varies widely depending on the specific substance or medication being used. For example, antiviral medications targeting avian influenza viruses may inhibit viral replication by interfering with the viral life cycle, often through mechanisms such as blocking viral entry into host cells or inhibiting viral neuraminidase activity.

Pharmacodynamics

Pharmacodynamics for avian-targeting drugs can include effects on avian physiology, such as modulation of immune response, reduction of viral load, or treatment of bacterial infections. The efficacy and effects depend on the specific condition being treated and the drug's pharmacological profile.

Pharmacokinetics

Pharmacokinetics will differ based on the specific substance being referenced. Typically, this includes absorption, distribution, metabolism, and excretion profiles that are unique to the drug class. In avian species, factors such as species-specific metabolism and physiological differences play crucial roles in how drugs are processed.

Pregnancy

Not enough data available regarding safety in pregnancy. Use with caution and only if the benefits outweigh the risks.

Breast-feeding

Limited data available. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: encephalomyelitis

Encephalomyelitis is an inflammatory condition affecting both the brain (encephalitis) and the spinal cord (myelitis). It can be caused by viral infections, autoimmune responses, or other infectious agents. The clinical presentation varies but commonly includes symptoms such as fever, headache, confusion, seizures, and neurological deficits. Treatment is generally supportive, and in some cases, corticosteroids or antiviral medications may be indicated depending on the underlying cause.

Indications

  • Viral infections leading to encephalomyelitis
  • Autoimmune conditions, such as multiple sclerosis
  • Post-infectious encephalomyelitis
  • Paraneoplastic syndromes affecting the CNS

Dosage

Children: Refer to clinical guidelines based on specific underlying causes. Dosing varies widely depending on the medication used and the child's condition.

Adults: Refer to clinical guidelines based on specific underlying causes. Treatment may include supportive care, corticosteroids for inflammation, or antiviral medications as appropriate.

Mechanism of action

The mechanism of encephalomyelitis varies depending on the causative agent. In viral encephalomyelitis, the virus typically invades the central nervous system (CNS), leading to direct neuronal damage and an inflammatory response. This may involve the activation of immune cells such as microglia and the release of pro-inflammatory cytokines, resulting in neuronal injury and dysfunction.

Pharmacodynamics

In the case of autoimmune encephalomyelitis, such as multiple sclerosis, the body’s immune system mistakenly attacks the myelin sheath covering nerves, leading to demyelination and impaired nerve conduction. The inflammatory response can cause both acute symptoms and chronic neurological deficits. Pharmacological agents like corticosteroids are used to suppress the immune response and reduce inflammation.

Pharmacokinetics

Pharmacokinetic profiles vary widely based on the treatment administered rather than the condition itself. For example, corticosteroids are typically well absorbed orally with variable bioavailability. They undergo hepatic metabolism and are excreted primarily in urine. The half-life and clearance depend on the specific steroid used. In contrast, antiviral agents would have different absorption, distribution, metabolism, and excretion characteristics.

Pregnancy

The safety of encephalomyelitis treatments during pregnancy depends on the specific medication used and the condition being treated. Consult relevant clinical guidelines and pharmacological references.

Breast-feeding

The effects of encephalomyelitis treatments on breastfeeding vary based on the specific drug. It is essential to consult with healthcare professionals regarding the safety of treatment during lactation.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Specific storage instructions may depend on the formulation and specific treatment used.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: gallisepticum

Gallisepticum is an antibiotic that is primarily used in veterinary medicine, particularly for the treatment of infections in poultry. It belongs to the class of drugs known as macrolides, which are characterized by their lactone rings and their ability to inhibit bacterial protein synthesis. Gallisepticum has been shown to be effective against a variety of Gram-positive and some Gram-negative bacteria.

Indications

  • Bacterial infections in poultry
  • Respiratory infections
  • Enteritis
  • Bacterial pneumonia

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Adults: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Mechanism of action

Gallisepticum works by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. This action prevents the translocation of peptides and halts the growth of bacteria, making it bacteriostatic. Its selectivity for bacterial ribosomes over mammalian ribosomes contributes to its therapeutic efficacy and safety profile.

Pharmacodynamics

The pharmacodynamic profile of gallisepticum indicates that it is effective at low concentrations against susceptible microorganisms. The drug exhibits a time-dependent killing effect, meaning that the duration of exposure at therapeutic levels is critical for achieving optimal antibacterial activity. Resistance may develop through various mechanisms, including methylation of adenine residues in the 23S rRNA, which decreases drug binding.

Pharmacokinetics

Gallisepticum is well absorbed from the gastrointestinal tract when administered orally. It undergoes extensive metabolism in the liver, with a significant first-pass effect. The elimination half-life varies depending on the species but generally ranges from several hours to a day. The drug is primarily excreted through bile and urine, with a minor fraction excreted unchanged. Its distribution in tissues is wide, allowing effective penetration into respiratory tissues.

Pregnancy

There is limited data on the use of gallisepticum during pregnancy. It is advisable to use caution and consult with a healthcare provider.

Breast-feeding

There is insufficient information regarding the excretion of gallisepticum in human milk. Caution is recommended if administered during breastfeeding.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: mycoplasma

Mycoplasma refers to a genus of bacteria that are notable for their lack of a cell wall, making them inherently resistant to antibiotics that target cell wall synthesis. They are some of the smallest self-replicating organisms and can cause a variety of diseases in humans, including respiratory infections and atypical pneumonia. Mycoplasma pneumoniae is the most clinically significant species and is known to cause infections primarily in children and young adults.

Indications

  • Mycoplasma pneumonia
  • Atypical pneumonia
  • Respiratory tract infections
  • Sinusitis
  • Bronchitis
  • Chronic cough

Dosage

Children: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment

Adults: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment.

Mechanism of action

Mycoplasma species, particularly Mycoplasma pneumoniae, adhere to the respiratory epithelial cells and disrupt normal cellular processes. They utilize surface proteins and lipids to anchor themselves to host cells, leading to cell damage through inflammatory responses. They do not produce toxins but can induce host immune responses that contribute to the pathogenicity of the infection.

Pharmacodynamics

Mycoplasma are unique bacteria that lack a cell wall, which makes them resistant to many common antibiotics, such as penicillins and cephalosporins. The treatment of infections caused by Mycoplasma typically involves the use of antibiotics that target protein synthesis, such as macrolides (e.g., azithromycin) or tetracyclines (e.g., doxycycline). These antibiotics inhibit bacterial growth by disrupting essential processes within the bacteria, leading to cell death or stasis.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat Mycoplasma infections can vary. For example, macrolides are well-absorbed orally and have good tissue penetration, allowing them to reach the site of infection effectively. They are metabolized in the liver and excreted primarily through bile. Tetracyclines also have good oral bioavailability and are distributed widely in body tissues, but should be avoided in children under 8 years due to potential effects on bone and tooth development. The half-lives of these antibiotics can range from several hours to a day, depending on the specific drug and patient factors.

Pregnancy

Mycoplasma infections should be treated with caution during pregnancy. The use of antibiotics may be necessary, but the choice of medication should consider safety profiles and potential risks to the fetus.

Breast-feeding

Caution is advised when treating Mycoplasma infections in breastfeeding individuals. Certain antibiotics may be excreted in breast milk, so a risk-benefit assessment is essential.

Storage

Store in a cool, dry place away from direct sunlight. Specific conditions may vary depending on the antibiotic used for treatment.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: virus

Viruses are submicroscopic infectious agents that replicate only inside the living cells of an organism. They are composed of genetic material (either DNA or RNA) surrounded by a protein coat and, in some cases, an outer lipid envelope. Viruses can infect all types of life forms, from animals and plants to microorganisms, including bacteria (bacteriophages). They are responsible for a wide range of diseases, from the common cold to serious conditions such as HIV/AIDS, influenza, and COVID-19.

Indications

  • Influenza
  • HIV/AIDS
  • Hepatitis B and C
  • Herpes simplex virus infections
  • Cytomegalovirus infections
  • COVID-19
  • Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.